Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > WOW
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(599)
•••
Comment by Bigginvestoron Feb 27, 2021 10:20am
182 Views
Post# 32678603

RE:RE:WOW

RE:RE:WOW
Moonshiner592 wrote:

THORZEUS2019 wrote: Seeing a lot of optimism here. I have this many shares, I'll sell for this much $$$.. Let's get real people. Come down from your cloud. For all we know, it could all turn out to be fairy dust and unicorn piss... The stock just started trading after a long halt. Give it time to breath. Then celebrate. Right now, it's like you know the outcome, but the game just began

 

... ahhh ... "fairy dust and unicorn piss"? .. are you sure? ..  if that were true we'd be seeing a sp of less than 2 cents.. look at the volume ... we're almost at 7 cents ... 

Bro - that ain't no unicorn!



yea this guy is asleep there is no piss or fairy dust here volume and I guess he didn't read the the Nitric oxide can prevent covid19 and the common cold in the NR. And the new company name this is for real man Rob was waiting to announce this .when everyone thought the company was done and never going to be in unhalted again lol this was a big surprise so all the none believers even me. now I'm a full believer so sit back and watch this thing take off ..
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities